Is IMCR or INAB more undervalued in 2026?

CirclFi compares Immunocore Holdings plc (IMCR) and IN8bio, Inc. (INAB) using 13 institutional-grade valuation models. IMCR has a Quality of Company score of 8.2/10 while INAB scores 3.2/10.

Which is a better buy — IMCR or INAB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IMCR and INAB valuations compare?

IMCR at $28.89 and INAB at $1.87 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IMCR vs INAB Valuation Comparison 2026 — Intrinsic Value Analysis

IMCR

Biological Products, (No Diagnostic Substances)

Immunocore Holdings plc

Quality

8.2

out of 10

Value Trap

SAFE

Price

$28.89

Last close

Models

12/13

Active

INAB

Biological Products, (No Diagnostic Substances)

IN8bio, Inc.

Quality

3.2

out of 10

Value Trap

LOW

Price

$1.87

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	IMCR Fair Value	IMCR Upside	INAB Fair Value	INAB Upside
Bayesian DCF	Intrinsic	$14.45	-50.0%	$1.54	-17.5%
Earnings Power Value	Intrinsic	$28.68	+1.9%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$5.69	-80.3%	$3.60	+92.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMCR vs INAB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMCR vs INAB — Which Stock Is More Undervalued?

IMCR scores higher with a 8.2/10 quality rating vs INAB's 3.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immunocore Holdings plc (IMCR) and IN8bio, Inc. (INAB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMCR currently trades at $28.89 with a QOC of 8.2/10, while INAB trades at $1.87 with a QOC of 3.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).